Business Description
AIM ImmunoTech Inc
NAICS : 325414
SIC : 2836
ISIN : US00901B3033
Total Employee Number:
21Description
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.29 | |||||
Equity-to-Asset | 0.25 | |||||
Debt-to-Equity | 2.15 | |||||
Debt-to-EBITDA | -0.38 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -76.35 | |||||
Beneish M-Score | -3.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -43.1 | |||||
3-Year EBITDA Growth Rate | 42 | |||||
3-Year EPS without NRI Growth Rate | 38.6 | |||||
3-Year FCF Growth Rate | 41 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 53.47 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.8 | |||||
9-Day RSI | 37.16 | |||||
14-Day RSI | 40.74 | |||||
3-1 Month Momentum % | -12.69 | |||||
6-1 Month Momentum % | -60.28 | |||||
12-1 Month Momentum % | -94.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.01 | |||||
Quick Ratio | 1.01 | |||||
Cash Ratio | 0.96 | |||||
Days Payable | 10972.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -85.6 | |||||
Shareholder Yield % | -152.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -29.79 | |||||
Operating Margin % | -10926.6 | |||||
Net Margin % | -14123.4 | |||||
EBITDA Margin % | -12860.64 | |||||
FCF Margin % | -12417.02 | |||||
OCF Margin % | -12037.23 | |||||
ROA % | -219.53 | |||||
ROIC % | -171.33 | |||||
3-Year ROIIC % | 595.03 | |||||
ROC (Joel Greenblatt) % | -2376.93 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.21 | |||||
PB Ratio | 1.14 | |||||
Price-to-Tangible-Book | 4.95 | |||||
EV-to-EBIT | -0.56 | |||||
EV-to-EBITDA | -0.57 | |||||
EV-to-Revenue | 73.7 | |||||
EV-to-Forward-Revenue | 105.87 | |||||
EV-to-FCF | -0.59 | |||||
Price-to-GF-Value | 0.11 | |||||
Price-to-Median-PS-Value | 0.07 | |||||
Earnings Yield (Greenblatt) % | -178.57 | |||||
FCF Yield % | -141.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:AIM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AIM ImmunoTech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.094 | ||
| EPS (TTM) ($) | -7.293 | ||
| Beta | 1.5652 | ||
| 3-Year Sharpe Ratio | -2.59 | ||
| 3-Year Sortino Ratio | -2.13 | ||
| Volatility % | 67.06 | ||
| 14-Day RSI | 40.74 | ||
| 14-Day ATR ($) | 0.074719 | ||
| 20-Day SMA ($) | 0.37779 | ||
| 12-1 Month Momentum % | -94.17 | ||
| 52-Week Range ($) | 0.21 - 20.32967 | ||
| Shares Outstanding (Mil) | 27.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AIM ImmunoTech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AIM ImmunoTech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-16 11:00 | In 163 days | ||
| Third quarter earnings results for 2026 | 2026-11-17 | In 133 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 38 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.26 (-5.98%) | ||
| Virtual Investor Closing Bell Featuring AIM ImmunoTech Inc. | 2026-04-16 16:00 | 0.55 (-5.91%) | ||
| Annual report for 2025 | 2026-03-27 | 0.69 (-10.19%) | ||
| Virtual Investor Closing Bell Event | 2026-02-19 16:00 | 1.19 (+4.39%) | ||
| Corporate Connect Webinar | 2026-02-11 13:40 | 0.98 (+3.77%) | ||
| 1.001:1 Stock Split | 2026-01-09 | 1.34 (+4.69%) | ||
| General meeting for 2025 | 2025-12-16 11:00 | 1.32 (-7.69%) |
Show
Entries
AIM ImmunoTech Inc Frequently Asked Questions
What is AIM ImmunoTech Inc(AIM)'s stock price today?
The current price of AIM is $0.30. The 52 week high of AIM is $20.33 and 52 week low is $0.21.
When is next earnings date of AIM ImmunoTech Inc(AIM)?
The next earnings date of AIM ImmunoTech Inc(AIM) is 2026-08-14 Est..
Does AIM ImmunoTech Inc(AIM) pay dividends? If so, how much?
AIM ImmunoTech Inc(AIM) does not pay dividend.
Guru Commentaries on AMEX:AIM
No articles.
Press Release
Articles on AIM ImmunoTech Inc
No articles.
Headlines
See More- 1
Jun 15, 2026
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Benzinga • 7:01am
Jun 09, 2026
AIM ImmunoTech announces $2.65M financing priced at-market
Seeking Alpha • 8:54am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers